TPST

Tempest Therapeutics, Inc.

Price Chart

Latest Quote

$1.25

+0.00 (+0.00%)

Current Price

Previous Close	$1.25
Open	$1.24
Day High	$1.29
Day Low	$1.24
Volume	58,458

Fetched: 2026-06-18T11:27:33

Stock Information

Shares Outstanding	14.81M
Total Debt	$7.85M
Cash Equivalents	$1.80M
Net Income	$-43.10M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$18.51M
EPS (TTM)	$-5.70
Exchange	NCM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$24.56M
Income	$-43.10M
Book/sh	$1.35
Cash/sh	$0.12
Employees	4

Financial Ratios

Quick Ratio	0.55
Current Ratio	0.74
Debt/Eq	955.47

Returns & Margins

ROA	-61.69%
ROE	-721.00%

Ownership

Insider Ownership	34.30%
Institutional Ownership	28.49%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.03
P/B	0.92

Analyst Data

Recommendation	none
Target Price	$11.00

Technical Indicators

SMA20	$1.45
SMA50	$1.73
SMA200	$4.52
RSI	7.14
ATR	0.0786

Shares Float	9.57M
Short Float	5.42%
Short Ratio	2.52
Rel Volume	0.59

Performance History

Week	-1.57%
Month	-31.32%
Quarter	-42.13%
6 Months	-57.48%
YTD	-57.63%
Year	-81.88%
3 Years	-92.93%
5 Years	-99.53%
10 Years	-99.99%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-17	$1.25	58,600
2026-06-16	$1.25	64,700
2026-06-15	$1.25	70,700
2026-06-12	$1.26	37,800
2026-06-11	$1.25	41,400
2026-06-10	$1.27	27,500
2026-06-09	$1.27	73,000
2026-06-08	$1.27	79,000
2026-06-05	$1.27	105,300
2026-06-04	$1.30	106,500
2026-06-03	$1.27	118,800
2026-06-02	$1.31	265,600
2026-06-01	$1.45	193,300
2026-05-29	$1.53	239,500
2026-05-28	$1.73	107,000
2026-05-27	$1.79	47,100
2026-05-26	$1.77	113,000
2026-05-22	$1.86	58,900
2026-05-21	$1.81	59,500
2026-05-20	$1.86	103,500
2026-05-19	$1.78	94,200
2026-05-18	$1.82	43,600

About Tempest Therapeutics, Inc.

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.

📰 Latest News

New Strong Buy Stocks for April 10th

Zacks • 2026-04-10T08:32:00Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$207,000	$1,316,000	$1,449,000	$1,618,000
Total Expenses	$26,575,000	$42,026,000	$29,157,000	$34,640,000
Net Non Operating Interest Income Expense	$313,000	$183,000	$-334,000	$-1,018,000
Interest Expense Non Operating	$207,000	$1,316,000	$1,449,000	$1,618,000
Operating Expense	$26,575,000	$42,026,000	$29,157,000	$34,640,000
General And Administrative Expense	$13,969,000	$13,550,000	$11,659,000	$12,113,000
Other Income Expense	-	-	$15,000	$-51,000
Other Non Operating Income Expenses	-	-	$15,000	$-51,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-26,262,000	$-41,843,000	$-29,491,000	$-35,709,000
Net Interest Income	$313,000	$183,000	$-334,000	$-1,018,000
Interest Income	$520,000	$1,499,000	$1,115,000	$600,000
Normalized Income	$-26,262,000	$-41,843,000	$-29,491,000	$-35,709,000
Net Income From Continuing And Discontinued Operation	$-26,262,000	$-41,843,000	$-29,491,000	$-35,709,000
Total Operating Income As Reported	$-26,575,000	$-42,026,000	$-29,157,000	$-34,640,000
Net Income Common Stockholders	$-26,262,000	$-41,843,000	$-29,491,000	$-35,709,000
Net Income	$-26,262,000	$-41,843,000	$-29,491,000	$-35,709,000
Net Income Including Noncontrolling Interests	$-26,262,000	$-41,843,000	$-29,491,000	$-35,709,000
Net Income Continuous Operations	$-26,262,000	$-41,843,000	$-29,491,000	$-35,709,000
Pretax Income	$-26,262,000	$-41,843,000	$-29,491,000	$-35,709,000
Interest Income Non Operating	$520,000	$1,499,000	$1,115,000	$600,000
Operating Income	$-26,575,000	$-42,026,000	$-29,157,000	$-34,640,000
Per Share
Diluted EPS	$-6.33	$-19.50	$-24.83	$-40.17
Basic EPS	$-6.33	$-19.50	$-24.83	$-40.17
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-25,789,000	$-40,138,000	$-27,661,000	$-33,453,000
Reconciled Depreciation	$266,000	$389,000	$381,000	$638,000
EBITDA (Bullshit earnings)	$-25,789,000	$-40,138,000	$-27,661,000	$-33,453,000
EBIT	$-26,055,000	$-40,527,000	$-28,042,000	$-34,091,000
Diluted Average Shares	$4,148,815	$3,382,432	$1,185,861	$888,947
Basic Average Shares	$4,148,815	$3,382,432	$1,185,861	$888,947
Diluted NI Availto Com Stockholders	$-26,262,000	$-41,843,000	$-29,491,000	$-35,709,000
Tax Provision	$0	$0	$0	$0
Research And Development	$12,606,000	$28,476,000	$17,498,000	$22,527,000
Selling General And Administration	$13,969,000	$13,550,000	$11,659,000	$12,113,000
Other Gand A	$13,969,000	$13,550,000	$11,659,000	$12,113,000

Fetched: 2026-06-17

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$6,668,000	$19,126,000	$26,768,000	$18,111,000
Total Assets	$16,931,000	$41,488,000	$51,603,000	$46,089,000
Total Non Current Assets	$8,662,000	$10,014,000	$11,240,000	$13,139,000
Other Non Current Assets	$517,000	$485,000	$448,000	$429,000
Current Assets	$8,269,000	$31,474,000	$40,363,000	$32,950,000
Other Current Assets	$355,000	$535,000	$96,000	$263,000
Prepaid Assets	$207,000	$671,000	$1,037,000	$1,007,000
Cash Cash Equivalents And Short Term Investments	$7,707,000	$30,268,000	$39,230,000	$31,230,000
Cash And Cash Equivalents	$7,707,000	$30,268,000	$39,230,000	$31,230,000
Receivables	-	-	$0	$450,000
Other Receivables	-	-	-	$450,000
Notes Receivable	-	-	-	-
Debt
Total Debt	$8,141,000	$15,365,000	$20,661,000	$22,114,000
Long Term Debt And Capital Lease Obligation	$6,949,000	$8,142,000	$15,424,000	$20,701,000
Current Debt And Capital Lease Obligation	$1,192,000	$7,223,000	$5,237,000	$1,413,000
Current Debt	-	$6,354,000	$4,285,000	-
Other Current Borrowings	-	$6,354,000	$4,285,000	-
Long Term Debt	-	-	$6,264,000	$10,371,000
Liabilities
Total Liabilities Net Minority Interest	$10,263,000	$22,362,000	$24,835,000	$27,978,000
Total Non Current Liabilities Net Minority Interest	$6,949,000	$8,142,000	$15,424,000	$20,701,000
Current Liabilities	$3,314,000	$14,220,000	$9,411,000	$7,277,000
Payables And Accrued Expenses	$1,975,000	$5,235,000	$2,631,000	$4,616,000
Interest Payable	$0	$59,000	$113,000	$97,000
Payables	$1,038,000	$2,450,000	$845,000	$1,108,000
Accounts Payable	$1,038,000	$2,450,000	$845,000	$1,108,000
Equity
Common Stock Equity	$6,668,000	$19,126,000	$26,768,000	$18,111,000
Total Equity Gross Minority Interest	$6,668,000	$19,126,000	$26,768,000	$18,111,000
Stockholders Equity	$6,668,000	$19,126,000	$26,768,000	$18,111,000
Retained Earnings	$-233,368,000	$-207,106,000	$-165,263,000	$-135,772,000
Preferred Securities Outside Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$4,927,161	$3,382,432	$1,695,788	$809,118
Share Issued	$4,927,161	$3,382,432	$1,695,788	$809,118
Tangible Book Value	$6,668,000	$19,126,000	$26,768,000	$18,111,000
Invested Capital	$6,668,000	$25,480,000	$37,317,000	$28,482,000
Working Capital	$4,955,000	$17,254,000	$30,952,000	$25,673,000
Capital Lease Obligations	$8,141,000	$9,011,000	$10,112,000	$11,743,000
Total Capitalization	$6,668,000	$19,126,000	$33,032,000	$28,482,000
Additional Paid In Capital	$240,031,000	$226,229,000	$192,009,000	$153,872,000
Capital Stock	$5,000	$3,000	$22,000	$11,000
Common Stock	$5,000	$3,000	$22,000	$11,000
Long Term Capital Lease Obligation	$6,949,000	$8,142,000	$9,160,000	$10,330,000
Current Capital Lease Obligation	$1,192,000	$869,000	$952,000	$1,413,000
Pensionand Other Post Retirement Benefit Plans Current	$147,000	$1,762,000	$1,543,000	$1,248,000
Current Accrued Expenses	$937,000	$2,785,000	$1,786,000	$3,508,000
Net PPE	$8,145,000	$9,529,000	$10,792,000	$12,710,000
Accumulated Depreciation	$-1,453,000	$-1,320,000	$-1,025,000	$-1,361,000
Gross PPE	$9,598,000	$10,849,000	$11,817,000	$14,071,000
Leases	$198,000	$201,000	$235,000	$882,000
Other Properties	$8,986,000	$10,128,000	$11,085,000	$1,061,000
Machinery Furniture Equipment	$414,000	$520,000	$497,000	$478,000
Properties	$0	$0	$0	$0
Buildings And Improvements	-	-	$9,952,000	$11,650,000

Fetched: 2026-06-17

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-26,820,000	$-33,462,000	$-27,527,000	$-31,634,000
Operating Activities
Operating Cash Flow	$-26,820,000	$-33,027,000	$-27,357,000	$-31,072,000
Cash Flow From Continuing Operating Activities	$-26,820,000	$-33,027,000	$-27,357,000	$-31,072,000
Investing Activities
Investing Cash Flow	$0	$-435,000	$-170,000	$-562,000
Cash Flow From Continuing Investing Activities	$0	$-435,000	$-170,000	$-562,000
Capital Expenditure	-	$-435,000	$-170,000	$-562,000
Net Other Investing Changes	-	-	-	-
Financing Activities
Issuance Of Capital Stock	$7,329,000	$28,591,000	$35,602,000	$8,861,000
Financing Cash Flow	$4,259,000	$24,500,000	$35,602,000	$11,403,000
Cash Flow From Continuing Financing Activities	$4,259,000	$24,500,000	$35,602,000	$11,403,000
Net Common Stock Issuance	$7,329,000	$28,591,000	$35,602,000	$8,861,000
Common Stock Issuance	$7,329,000	$28,591,000	$35,602,000	$8,861,000
Net Preferred Stock Issuance	-	-	-	$7,281,000
Preferred Stock Issuance	-	-	-	$7,281,000
Net Other Financing Charges	-	-	-	-
Other
Repayment Of Debt	$-6,426,000	$-4,398,000	$0	$-4,739,000
Interest Paid Supplemental Data	$192,000	$1,177,000	$1,249,000	$1,539,000
Income Tax Paid Supplemental Data	$43,000	$54,000	$191,000	$18,000
End Cash Position	$8,150,000	$30,711,000	$39,673,000	$31,598,000
Beginning Cash Position	$30,711,000	$39,673,000	$31,598,000	$51,829,000
Changes In Cash	$-22,561,000	$-8,962,000	$8,075,000	$-20,231,000
Proceeds From Stock Option Exercised	$3,356,000	$307,000	$0	$7,281,000
Net Issuance Payments Of Debt	$-6,426,000	$-4,398,000	$0	$-4,739,000
Net Long Term Debt Issuance	$-6,426,000	$-4,398,000	$0	$-4,739,000
Long Term Debt Payments	$-6,426,000	$-4,398,000	$0	$-4,739,000
Net PPE Purchase And Sale	$0	$-435,000	$-170,000	$-562,000
Purchase Of PPE	$0	$-435,000	$-170,000	$-562,000
Change In Working Capital	$-5,130,000	$1,613,000	$-2,677,000	$868,000
Change In Other Current Liabilities	$-870,000	$-1,101,000	$-1,631,000	$-1,501,000
Change In Payables And Accrued Expense	$-4,875,000	$2,824,000	$-1,239,000	$1,454,000
Change In Accrued Expense	$-3,463,000	$1,219,000	$-976,000	$1,453,000
Change In Interest Payable	$-59,000	$-54,000	$16,000	$-256,000
Change In Payable	$-1,412,000	$1,605,000	$-263,000	$1,000
Change In Account Payable	$-1,412,000	$1,605,000	$-263,000	$1,000
Change In Prepaid Assets	$615,000	$-110,000	$193,000	$915,000
Other Non Cash Items	$1,188,000	$1,511,000	$1,884,000	$1,570,000
Stock Based Compensation	$3,118,000	$5,303,000	$2,546,000	$1,561,000
Depreciation Amortization Depletion	$266,000	$389,000	$381,000	$638,000
Depreciation And Amortization	$266,000	$389,000	$381,000	$638,000
Depreciation	$266,000	$389,000	$381,000	$638,000
Net Income From Continuing Operations	$-26,262,000	$-41,843,000	$-29,491,000	$-35,709,000
Issuance Of Debt	-	-	-	$0
Long Term Debt Issuance	-	-	-	$0

Fetched: 2026-06-17